Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Bano, Joanie, Chames, Patrick, Baty, Daniel, Kerfelec, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698871/
https://www.ncbi.nlm.nih.gov/pubmed/31557983
http://dx.doi.org/10.3390/antib5010001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698871/
https://www.ncbi.nlm.nih.gov/pubmed/31557983
http://dx.doi.org/10.3390/antib5010001

Ejemplares similares